Clinical Trials Browser

Phase 3 × Has announcements × venetoclax × Clear all

NCT03336333 2026-03-09

SEQUOIA

Phase 3 Active not recruiting

590 enrolled 12 charts 1 FDA

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02242942 2025-11-06

Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

Phase 3 Completed

445 enrolled 22 charts 1 FDA

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03069352 2025-09-30

A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

Phase 3 Completed

211 enrolled 30 charts 2 FDA

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT02993523 2025-08-19

Viale-a

Phase 3 Active not recruiting

443 enrolled 14 charts 2 FDA

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03836261 2024-12-27

AMPLIFY

Phase 3 Active not recruiting

984 enrolled 1 FDA

LymphoidOther hematologic neoplasm

Leukemia, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02005471 2023-10-17

MURANO

Phase 3 Completed

389 enrolled 35 charts 2 FDA

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell